Solving Vector Yield Challenges in In Vivo CGT

What does it take to turn breakthrough biology into successful in vivo therapies?

As innovations in synthetic biology, RNA editing, and gene therapy continue to accelerate, vector design and manufacturing remain the critical link between scientific discovery and patient impact.

Join Chief Editor Erin Harris for a special Cell & Gene Live discussion with Robert Bell, Ph.D., CSO at Ascidian Therapeutics, and Karen Kozarsky, Ph.D., Founder of Vector BioPartners. Together, they’ll explore how capsid engineering affects transduction efficiency, the tradeoffs between tissue specificity and manufacturability, and what manufacturing teams need to know about real-world in vivo performance.

Don’t miss this expert conversation on the challenges and opportunities shaping the future of in vivo cell and gene therapies.

Registration is free.